Impact of vitamin D3 dietary supplement matrix on clinical response.

ABSTRACT:

Context

As a result of research suggesting increased health risk with low serum 25-hydroxycholecalciferol (25(OH)D), health care providers are measuring it frequently. Providers and patients are faced with treatment choices when low status is identified.

Objective

To compare the safety and efficacy of three vitamin D3 dietary supplements with different delivery matrices.

Setting and design

A 12-week, parallel group, single-masked, clinical trial was conducted in Seattle, Washington and Kailua Kona, Hawaii. Sixty-six healthy adults with (25(OH)D) <33 ng/mL were randomly assigned to take one of three D3 supplements, ie, a chewable tablet (TAB), an oil-emulsified drop (DROP), or an encapsulated powder (CAP) at a label-claimed dose of 10,000 IU/day. Actual D3 content was

SUBMITTER: Traub ML 

PROVIDER: S-EPMC4121030 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature